With cybercrime costs projected to reach $10.5 trillion annually by 2025, the pharmaceutical supply chain, rich in intellectual property (IP), faces escalating risks that demand robust security measures. In response to these growing threats, resilience within the...
As the pharmaceutical industry continues to grow and evolve, so does the amount of unstructured data that companies must navigate. Pharmaceutical companies accumulate vast amounts of data each year, spanning all stages of research and development. With clinical...
Drug development is fraught with challenges, as evidenced by the high rate of candidate failures during clinical trials due to inadequate evidence or ambiguous data. However, the landscape is shifting with the rise of collaborative data initiatives. These initiatives...
The pharmaceutical industry is experiencing a rapid surge in data generation, driven by advances in research, clinical trials, and patient data collection. While this data explosion offers immense potential for innovation and improving healthcare outcomes, it also...
